Project Grant R56AI201418
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $777K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $3,040,700 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance xenotransplantation without immunosuppressive maintenance. The award funds two integrated research projects and three supporting cores investigating methods to achieve donor-specific immunologic unresponsiveness in xenotransplantation using genetically...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $769,846 on August 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms governing interspecies chimeric hearts for xenotransplantation. The research develops strategies to engineer porcine embryonic hosts deficient in key developmental regulatory factors, creating a developmental niche for donor stem cells to populate and generate...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded New York University $2.064597 million on April 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct pig-to-human xenotransplantation research using a decedent model. NYU Langone will perform 20 thymokidney xenotransplants in human decedents and monitor clinical, immunological, and physiological outcomes for up to 60 days post-transplant....
- The National Institute of Allergy and Infectious Diseases awarded $492,250 to Terasaki Institute for Biomedical Innovation on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a vascularized porcine liver on-a-chip platform capable of modeling human xenoimmune responses toward porcine liver xenografts. The award supports research addressing xenogeneic rejection, coagulation dysregulation, and thrombocytopenia that currently limit porcine...
- The National Institute of Allergy and Infectious Diseases awarded the University of Maryland, Baltimore $770,199 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how metabolic rewiring driven by gut microbiome changes influences immune outcomes in chronic cardiac transplant rejection. The research employs a murine model of chronic cardiac rejection with full MHC mismatch and clinically relevant chronic immunosuppression to study how...
- The National Institute of Allergy and Infectious Diseases awarded Boston Children's Hospital $847,299 on August 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate immunomodulatory mechanisms in allograft rejection. The project, titled "Regulation of Alloimmunity by Intragraft Endothelial Cells," examines how graft microvascular endothelial cells suppress alloimmune responses during transplant rejection. The research will characterize...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $251,324 on August 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop engineered organ transplants resistant to antibody-mediated rejection through synthetic biology platforms. The research focuses on designing signal-inducible, drug-controllable endopeptidases for localized antibody degradation within transplanted tissue. The award funds...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $427,625 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Maryland, Baltimore, effective August 1, 2025, through July 31, 2027. This award funds basic biomedical research investigating CD27-mediated immune suppression mechanisms in hematopoietic stem and progenitor cells (HSPCs), innate immune cells, and non-hematopoietic cells. The...
- The National Institute of Allergy and Infectious Diseases awarded the University of Connecticut Health Center $572,890 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to extend the longevity of implantable biomedical devices through therapeutic regulation of the foreign body response. The research targets the foreign body response (FBR)—an immune-mediated destructive process that occurs when biomaterial surfaces contact host biological systems and...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $233,125 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate a toolkit for studying 1-deoxy-D-xylulose 5-phosphate synthase (DXPS) as a driver of metabolic adaptation in bacterial pathogens. The research targets bacterial central metabolism as a route to novel antibacterial strategies, focusing on how pathogens remodel their metabolism to...